SG11201810915QA - Preparation of factor xa derivatives - Google Patents
Preparation of factor xa derivativesInfo
- Publication number
- SG11201810915QA SG11201810915QA SG11201810915QA SG11201810915QA SG11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA SG 11201810915Q A SG11201810915Q A SG 11201810915QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- suite
- south san
- protein
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 101710162629 Trypsin inhibitor Proteins 0.000 abstract 1
- 229940122618 Trypsin inhibitor Drugs 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000002753 trypsin inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIP0 I PCT omit VIII two III OH Oil moimommo (10) International Publication Number WO 2017/219034 A2 (51) International Patent Classification: C12N 9/64 (2006.01) CO7K 1/22 (2006.01) (21) International Application Number: PCT/US2017/038169 (22) International Filing Date: 19 June 2017 (19.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/351,841 17 June 2016 (17.06.2016) US (71) Applicant: PORTOLA PHARMACEUTICALS, INC. [US/US]; 270 E. Grand Ave., Suite 22, South San Francis- co, California 94080 (US). (72) Inventors: KARBARZ, Mark; c/o Portola Pharmaceuti- cals, Inc., 270 E. Grand Ave., Suite 22, South San Fran- cisco, California 94080 (US). CONLEY, Pamela B.; c/o Portola Pharmaceuticals, Inc., 270 E. Grand Ave., Suite 22, South San Francisco, California 94080 (US). LU, Genmin; c/o Portola Pharmaceuticals, Inc., 270 E. Grand Ave., Suite 22, South San Francisco, California 94080 (US). (74) Agent: NIE, Alex Y. et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 379 Lytton Avenue, Palo Alto, California 94301-1479 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) O N O (54) Title: PREPARATION OF FACTOR XA DERIVATIVES (57) : The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351841P | 2016-06-17 | 2016-06-17 | |
| PCT/US2017/038169 WO2017219034A2 (en) | 2016-06-17 | 2017-06-19 | Preparation of factor xa derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810915QA true SG11201810915QA (en) | 2019-01-30 |
Family
ID=60663351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810915QA SG11201810915QA (en) | 2016-06-17 | 2017-06-19 | Preparation of factor xa derivatives |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10604748B2 (en) |
| EP (2) | EP3926044A1 (en) |
| JP (3) | JP6959268B2 (en) |
| KR (1) | KR102373215B1 (en) |
| CN (2) | CN116425860A (en) |
| AU (2) | AU2017283720B2 (en) |
| BR (1) | BR112018075964A2 (en) |
| CA (1) | CA3027457A1 (en) |
| CL (2) | CL2018003654A1 (en) |
| CO (1) | CO2019000120A2 (en) |
| DK (1) | DK3472314T3 (en) |
| EA (1) | EA037815B1 (en) |
| ES (1) | ES2875538T3 (en) |
| HU (1) | HUE054597T2 (en) |
| IL (1) | IL263591B2 (en) |
| MX (1) | MX2018015873A (en) |
| PE (1) | PE20190661A1 (en) |
| PH (1) | PH12018502614A1 (en) |
| PL (1) | PL3472314T3 (en) |
| PT (1) | PT3472314T (en) |
| SG (1) | SG11201810915QA (en) |
| SI (1) | SI3472314T1 (en) |
| WO (1) | WO2017219034A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117729A1 (en) * | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| SG11201505627RA (en) * | 2013-01-24 | 2015-08-28 | Portola Pharm Inc | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES |
| KR102373215B1 (en) * | 2016-06-17 | 2022-03-10 | 포톨라 파마슈티컬스, 인코포레이티드 | Preparation of Factor Xa Derivatives |
| EP3810187A4 (en) * | 2018-06-19 | 2022-08-31 | Alexion Pharmaceuticals, Inc. | Antidotes to factor xa inhibitors |
| KR102337683B1 (en) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | Highly efficient anti-TFPI antibody composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189019A (en) * | 1990-04-23 | 1993-02-23 | Merck & Co., Inc. | Antistasin derived anticoagulant protein |
| US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| JPH1066572A (en) * | 1996-08-29 | 1998-03-10 | Showa Sangyo Co Ltd | Production of soybean trypsin inhibitor of high purity |
| ATE311366T1 (en) | 2000-02-29 | 2005-12-15 | Millennium Pharm Inc | BENZAMIDE AND SIMILAR FACTOR XA INHIBITORS |
| NZ567992A (en) | 2005-11-08 | 2011-05-27 | Millennium Pharm Inc | Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide, a factor Xa inhibitor |
| HUE052423T2 (en) | 2007-09-28 | 2021-04-28 | Alexion Pharma Inc | Antidotes for factor xa inhibitors and methods of using the same |
| MX2011004907A (en) | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents. |
| WO2010117729A1 (en) | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| JP6163304B2 (en) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Unit dose formulations of factor Xa inhibitor antidote and methods of use thereof |
| SG11201408028YA (en) * | 2012-06-14 | 2015-01-29 | Portola Pharm Inc | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
| US20140346397A1 (en) * | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| SG11201505627RA (en) | 2013-01-24 | 2015-08-28 | Portola Pharm Inc | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES |
| CN105579468A (en) * | 2013-09-24 | 2016-05-11 | 辉瑞大药厂 | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| CN107073082B (en) * | 2014-08-20 | 2021-04-30 | 博尔托拉制药公司 | Lyophilized formulations of factor XA antidotes |
| KR102373215B1 (en) * | 2016-06-17 | 2022-03-10 | 포톨라 파마슈티컬스, 인코포레이티드 | Preparation of Factor Xa Derivatives |
-
2017
- 2017-06-19 KR KR1020197000840A patent/KR102373215B1/en active IP Right Grant
- 2017-06-19 PE PE2018003241A patent/PE20190661A1/en unknown
- 2017-06-19 EP EP21164923.1A patent/EP3926044A1/en active Pending
- 2017-06-19 JP JP2018565888A patent/JP6959268B2/en active Active
- 2017-06-19 HU HUE17814267A patent/HUE054597T2/en unknown
- 2017-06-19 EA EA201990052A patent/EA037815B1/en not_active IP Right Cessation
- 2017-06-19 EP EP17814267.5A patent/EP3472314B1/en active Active
- 2017-06-19 AU AU2017283720A patent/AU2017283720B2/en active Active
- 2017-06-19 PT PT178142675T patent/PT3472314T/en unknown
- 2017-06-19 SG SG11201810915QA patent/SG11201810915QA/en unknown
- 2017-06-19 DK DK17814267.5T patent/DK3472314T3/en active
- 2017-06-19 CN CN202310427500.2A patent/CN116425860A/en active Pending
- 2017-06-19 PL PL17814267T patent/PL3472314T3/en unknown
- 2017-06-19 US US15/626,813 patent/US10604748B2/en active Active
- 2017-06-19 CA CA3027457A patent/CA3027457A1/en active Pending
- 2017-06-19 CN CN201780041530.2A patent/CN110167575B/en active Active
- 2017-06-19 SI SI201730865T patent/SI3472314T1/en unknown
- 2017-06-19 IL IL263591A patent/IL263591B2/en unknown
- 2017-06-19 BR BR112018075964-3A patent/BR112018075964A2/en unknown
- 2017-06-19 WO PCT/US2017/038169 patent/WO2017219034A2/en unknown
- 2017-06-19 ES ES17814267T patent/ES2875538T3/en active Active
- 2017-06-19 MX MX2018015873A patent/MX2018015873A/en unknown
-
2018
- 2018-12-11 PH PH12018502614A patent/PH12018502614A1/en unknown
- 2018-12-17 CL CL2018003654A patent/CL2018003654A1/en unknown
-
2019
- 2019-01-09 CO CONC2019/0000120A patent/CO2019000120A2/en unknown
-
2020
- 2020-01-10 US US16/740,001 patent/US10954504B2/en active Active
- 2020-06-25 CL CL2020001733A patent/CL2020001733A1/en unknown
-
2021
- 2021-03-09 US US17/196,172 patent/US11845966B2/en active Active
- 2021-10-07 JP JP2021165271A patent/JP7273918B2/en active Active
-
2023
- 2023-02-14 AU AU2023200825A patent/AU2023200825A1/en active Pending
- 2023-04-28 JP JP2023074627A patent/JP2023086970A/en active Pending
- 2023-11-08 US US18/505,022 patent/US20240076642A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810915QA (en) | Preparation of factor xa derivatives | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806302RA (en) | Inhibitors of receptor-interacting protein kinase 1 | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201810777WA (en) | Purification of multispecific antibodies | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201908549RA (en) | Automated quality control and spectral error correction for sample analysis instruments | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201407662WA (en) | Process for the preparation of treprostinil and derivatives thereof | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201907764PA (en) | Methods for screening infections | |
| SG11201407294UA (en) | Contamination identification system |